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ABSTRACT
ARSENIC IN DRINKING WATER CAUSES GENE EXPRESSION CHANGES IN
THE LIVER RELATED TO INFLAMMATION AND METABOLIC DYSFUNCTION
AND ACCELERATES ATHEROSCLEROSIS IN APOE-/- MICE.
Matthew R Zajack
August 5,2010
Arsenic exposure in drinking-water is a significant worldwide health
problem. It causes adverse human health effects, such as cancer, increases the
risks for others such as cardiovascular disease, and accelerates atherosclerosis.
In this study, we analyze arsenic-induced gene expression changes in the liver of
ApoE-knockout mice given 49 ppm arsenic in drinking-water. We hypothesize
chronic arsenic exposure accelerates atherosclerosis by disrupting liver
homeostasis, causing aberrant gene expression changes. Networks revealed
hubs on 3 stress-response MAP kinase pathways, ERK, JNK, and p38.
Pathways revealed mitochondrial dysfunction and oxidative phosphorylation
enrichment from the gene set. Transcription factor binding site analysis revealed
specific transcription factors Foxd 1, estrogen receptors, heat shock factor, Myc,
and Pparg. Taken together, results suggest metabolic function disruption in the
mitochondria related to oxidative stress and increased MAPK activity. Future
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studies should focus on arsenic's effects on mitochondria dealing with
metabolism and activation of ERK, JNK, and p38 MAPK pathways.
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CHAPTER 1
INTRODUCTION

Arsenic exposure

Arsenic exposure through drinking-water is a significant worldwide health
problem. Arsenic contaminates drinking water primarily through both natural
mineral deposits, tapped by groundwater wells, and anthropogenic sources,
through mining and industrial use[1-2].
The US Agency for Toxic Substances and Disease Registry (ATSDR)-a
division of the CDC-has, for over 13 years, listed arsenic as the number one
priority substance based on frequency, toxicity, and potential for human exposure
at facilities located at National Priorities List sites. To put this in perspective,
arsenic is ranked above lead (2), mercury (3), benzo(a)pyrene (9), and DDT (12)
in 2007. The US Environmental Protection Agency (EPA) set the maximum
contaminant level (MCl) for arsenic at 0.010 ppm (parts per million; 0.010 mg/l
As) or 10 ppb (parts per billion; 10 1J9/l As) in 2001, which is the same as the
World Health Organization (WHO) provisional guideline value set in 1993. Prior
to this regulation, the MCl was set at 0.050 ppm for both the EPA in 1976 and
WHO in 1963 [3]. In addition, the EPA set the public health goal for arsenic
1

exposure at 0 ppm. There are many areas in the United States in which
groundwater is naturally contaminated with arsenic (0.010 ppm or more)
including, but not limited to, Michigan, Texas, and parts of the southwestern
states of Arizona, Nevada, and California, although this estimate excludes many
rural, private, and unregulated wells for which data are unavailable [4-5]. In a
study by the EPA in 2000, of the 43,443 ground water systems queried, 2,302
had arsenic at concentrations> 10 ug/l (0.010 ppm), which is above the current
EPA MCl [6]. Additionally, there are reports of arsenic drinking-water
contamination from around the world, including Southeast Asia, China, Iran, and
Mexico, and many others [7-8], with some of these areas containing
concentrations as high as 1000 1J9/l arsenic dissolved in groundwater. longterm arsenic exposure increases the risk of many diseases, including
hyperpigmentation, keratosis, skin cancer, and internal cancers [9]. Additionally,
the EPA states health effects from long-term arsenic exposure include skin
damage, problems with circulatory systems, and an increased risk of cancer [10].
long-term exposure to arsenic in drinking-water has a plethora of human
health effects including increased risks of skin, bladder, and lung cancer [1-2].
Arsenic is excreted in the urine, primarily through the kidneys, within a few days
after ingestion. In a study by Chen et al conducted in northeastern Taiwan,
arsenic exposure at <10 1J9/l (0.010 ppm) arsenic for over 50 years from birth
significantly increased the risk of urinary cancer with a relative risk of 4.12 [11]. It
is also hypothesized that arsenic acts as a skin carcinogen by enhancing the
effects of ultraviolet (UV) radiation [12]. This is especially likely considering the
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aberrant effects that arsenic has in combination with polymorph isms in nucleotide
excision repair genes such as XPA and XPD [13]. Arsenic may also enter the
body through inhalation. A study at the National Cancer Institute by Lubin et al
reveals a linear relationship between lifetime cumulative arsenic exposure and
respiratory cancer mortality [14]. In fact, this study argues against a previously
postulated exposure threshold for carcinogenesis that was set at 150 IJg/L
(0.150 ppm) arsenic [15] by showing cumulative lifetime arsenic intake in smelter
workers in Tacoma, Washington unequivocally corresponded to < 30 IJg/L
(0.030 ppm) arsenic. However, cancer is not the only concern from long-term
arsenic exposure, cardiovascular disease risk is also an important consideration.
Non-cancer studies of the reproductive, neurological, cardiovascular,
respiratory, hematological, diabetic, and dermal effects of arsenic are of
significant interest, especially in cost-to-benefit estimates for drinking water
standards [2]. Early reports concerning the noncancer effects of inorganic
arsenic focused primarily on the blackfoot disease endemic in Taiwan that has
occurred since the early 20 th century and peaked in the last 1950's [16].
Bangladesh and West Bengal, in an effort to stave off bacterial contamination
persistent in surface drinking water sources, groundwater wells were dug by the
WHO for use by residents. After a period of years investigators started seeing
gangrene of the extremities, similar to the blackfoot disease seen in Taiwan,
among other diseases, and related it back to the artesian well water being
consumed by residents [17]. Blackfoot disease advances from coldness or
numbness of the extremities, to intermittent claudication, and finally to gangrene
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and surgical or spontaneous amputation. Engel et al [16] went on to explain that
manifestations such as blackfoot disease are only "the tip of the iceberg," and
that it is likely there is unseen systemic disease-he goes on to support it with
reports of mortality due to vascular causes such as atherosclerosis. Indeed,
vascular effects should be taken into consideration with respect to arsenic
exposure and will be discussed more fully below.
In addition to arsenic's direct effects on the vascular system, there are
studies implicating an association of arsenic with cardiovascular disease.
Arsenic induces atherogenesis by causing endothelial damage, endothelial
dysfunction, enhanced inflammatory activity, increased coagulability and
decreased fibrinolysis, smooth muscle cell proliferation, increased oxidative
stress, impaired nitric oxide balance, and induction of apoptosis. Arsenic has
also been found in epidemiological studies to be associated with hypertension
and diabetes mellitus [18]. Low-to-moderate levels of arsenic (11 IJg/L) in
drinking water in Michigan revealed an association with many diseases by
standardized mortality ratio (SMR); e.g. circulatory system (SMR, 1.11)
cerebrovascular disease (SMR, 1.19), diabetes mellitus (SMR, 1.28), and kidney
disease (SMR, 1.28) [5]. All of these could predispose, trigger, or aggravate
atherogenesis or are a consequence to atherosclerosis and are discussed below
in more detail.
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Cardiovascular disease and atherosclerosis
Cardiovascular disease is the leading cause of death worldwide.
Cardiovascular disease accounted for more than 34% of all deaths in the United
States in 2006, and the estimated direct and indirect cost of cardiovascular
disease is over $500 billion for 2010 [19]. Cardiovascular disease is
characterized by the dysfunction of blood vessels and the heart. Diseases
caused by cardiovascular disease are high blood pressure (hypertension),
coronary heart disease, heart failure, renal failure, and stroke. Atherosclerosis, a
disease of the large arteries, is the underlying cause of the majority of
cardiovascular events and in westernized societies is also the underlying cause
of about 50% of all deaths [20]. Atherosclerosis is a condition in which plaquecomposed of cholesterol, fat, calcium, and other SUbstances in the blood-builds
up in the inner linings of arteries.
Atherosclerosis is a progressive, multifactorial disease that is
characterized by the accumulation of lipids, inflammation, and scar tissue and
other fibrous elements in the arterial walls-the process below is summarized
from Harrison's Principles of Internal Medicine [21]. An abundance of circulating
cholesterol promotes accumulation of low-density lipoprotein (LDL) particles on
the outside and invading into the endothelial layer of the arterial wall, forming
fatty streaks. Once LDL particles are deposited below the endothelial layer,
away from circulating blood, they favor oxidative modification. These oxidized
LDL (oxLDL) particles may trigger a local inflammatory response, activating
inflammatory mediators such as leukocytes and macrophages. Macrophages will
5

engulf oxLDL and become cholesterol-rich foam cells. Accumulation of foam
cells forms a plaque and progresses the atherosclerotic lesion, releasing more
inflammatory markers. Under stable conditions, smooth muscle cells will
eventually proliferate into the macrophage-rich lesion area creating a fibrous
lesion and narrowing the artery. Alternatively, under certain conditions this
plaque may remain unstable, not forming a fibrous lesion, and rupture; a rupture
triggers blood clotting that may block the entire artery. Atherosclerosis is a
chronic process that occurs in multiple "steps" and is able to go into quiescence
for long periods of time to resume when conditions again favor lesion formation.
Inflammation plays an established fundamental role in mediating all stages
of atherosclerosis, from initiation through progression, and finally, thrombotic
complications of atherosclerosis [22]. Atherosclerosis is characterized by
recruitment of white blood cells, such as monocytes and leukocytes, to early
atherosclerotic lesions [20]. Normally, however, the endothelium does not
support binding of white blood cells. According to Libby et al [22], an event or
trigger, such as hypertension, smoking, insulin resistance, or an atherogenic diet
(a diet high in cholesterol and fats) is needed to stimulate endothelial cells to
begin to express pro-inflammatory molecules, including adhesion molecules that
will bind various leukocytes; once blood-derived inflammatory cells participate
with endothelial cells, they may perpetuate a local inflammatory response [22].
In this way, the inflammatory signal to initiate atherosclerosis need not be found
locally.
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Distant sources of inflammation may contribute to atherosclerosis [23].
The idea that a seemingly unrelated condition may contribute to complications of
another disease is not novel. For example, the hypothesis that an infection may
be associated with atherosclerosis, in fact, was suggested over 100 years ago by
Hektoen [24]. One such example is from the teeth in the case of gingivitis by
Ford et al [25]. Ford injected 6 week-old apoE-I- mice each either P. gingivalis or
C. pneumoniae, killed the mice at 18 or 34 weeks of age, and assessed
atherosclerotic lesion area. They showed all immunized mice developed lesions
greater than those of controls (p<0.05), but that those immunized with P.
gingiva lis developed larger atherosclerotic lesions than those with C.
pneumoniae (p<0.043).

Systemic inflammation through liver damage also contributes to
atherogenesis. In a case-control study by Brea et ai, nonalcoholic fatty liver
disease (NAFLD) is associated with atherosclerosis [26]. They assessed 93
patients with fatty liver and 40 controls for frequency and magnitude of
cardiovascular risk factors and measured carotid atherosclerosis by intima-media
thickness (IMT). They found patients with NAFLD had significantly more
abnormalities related to metabolic syndrome (MetS), including visceral adiposity,
hypertension, abnormal glucose metabolism, insulin resistance,
hypertriglyceridemia, and low HDL cholesterol (p<0.005). They suggest that
NAFLD is atherogenic beyond its association with MetS. They propose
mechanisms related to enhanced oxidative stress, reactive oxygen species
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causing increased circulating inflammatory milieu, and circulating C-reactive
protein (CRP) contributing to the inflammatory status in NAFLD.
Systemic inflammation contributing to atherosclerosis is widely accepted
and now being linked with many other diseases. Berg et al reviews evidence
supporting the hypothesis that adipose tissue plays a role in development of
systemic inflammatory state that contributes to CVD [27]. The review touches on
subjects such as innate immunity mediated solely through fat bodies activated by
NF-kB in metazoan species, toll-like receptors in mammals activating signal
transduction pathways activating mediators such as interleukin-6 (IL-6) and TNFalpha, and response to infections by IL-6, IL-11, and interferon-gamma (IFNgamma). Berg et al explains that obesity contributes to systemic inflammation by
causing increased expression of TNF-alpha, IL-6, PAI-1, CRP, fibrinogen, and
increases macrophage infiltration, and that the liver contributes to this condition.
Obesity also contributes to CVD via atherosclerosis,
hypercholesterolemia, insulin resistance and type 2 diabetes, and metabolic
syndrome [27-28]. Libby et al review a study that looks at clinical applications for
inflammation in atherosclerosis to limit cardiovascular events [29]. The JUPITER
trial is a placebo-controlled study to evaluate if people with some inflammation
(indicated by CRP) but below median levels of low-density lipoprotein (LDL)
would benefit from statin therapy. Endpoints of myocardial infarction (MI), stroke,
or cardiovascular death fell by 47% in rosuvastatin group compared to placebo
group (p<O.00001) with little cost in terms of unwanted effects. The study
provided further evidence that cardiovascular events can be reduced by LDL
8

lowering and an LDL-independent anti-inflammatory effect. The concept of
inflammation in atherosclerosis is no longer only theory and laboratory
investigation, it shows a promising role as a tool in the clinic to aid prevention
and management of cardiovascular disease [29]. Hotamisligil, in a review,
addresses metabolic and inflammatory responses as the core of metabolic
disorders such as obesity and CVD [28]. He discusses several topics related to
the mechanistic core of metabolic and inflammatory responses: Tumor Necrosis
Factor alpha (TNF-alpha), a proinflammatory cytokine, is overexpressed in
adipose tissues and acts to inhibit insulin action. Peroxisome-proliferator
activated receptor (PPAR) and liver X receptor (LXR) transcription factors inhibit
the inflammatory response in macrophages and adipocytes. c-Jun aminoterminal kinase (JNK) mediates insulin resistance, plays a critical role in liver
tissues, and promotes inflammatory gene expression through activator protein-1
(AP-1) and NF-kB. Obesity and type 2 diabetes are critically involved in many
processes that interact with metabolic dysfunction and inflammation[28]. Among
many transcription factors involved in stress-response, NF-kB is very sensitive to
arsenic-induced oxidative stress [30]. Normally, up-regulation of IKK leads to
degradation of IkB and in turn translocation of NF-kB to the nucleus where it is
activated. Ghosh et al have shown that arsenic in cardiomyocytes increased
ROS production and increased apoptotic cell death [30]. When they
administered a JNK and p38 MAPK inhibitor, NF-kB and IKK phosphorylation
was attenuated, suggesting that arsenic increases phosphorylation of p38 MAPK
and JNK MAPK that leads to NF-kB by IKK activation.
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Apolipoprotein E-knockout mouse is a model for atherosclerosis
The apolipoprotein E-knockout (ApoE-/-) mouse [31] is a powerful
investigatory model for atherosclerosis, especially considering that normal mice
are highly resistant to atherosclerosis. ApoE-/- mice are used extensively to
study the development of atherosclerosis.
Apolipoprotein E (apoE) is one of several evolutionarily conserved
lipoprotein genes. Its primary function is to mediate the receptor-mediated
removal of lipoproteins from the blood. ApoE is the primary ligand for the lowdensity lipoprotein receptor (LDLr) which mediates the removal of lipoprotein
remnants from circulation. ApoE-deficiency results in decreased removal of LDL
cholesterol, i.e. increasing "bad" cholesterol. This results in an increase in
overall cholesterol levels from 75 mg/dL in the normal (background strain) to
500 mg/dL in ApoE-/- mice. High levels of LDL and/or low levels of HDL
cholesterol are risk factors for atherosclerosis and CVD. Plump et al showed the
atherosclerotic lesions in ApoE-/- mice also accurately represent the extent and
severity of human atherosclerosis [31]. The ApoE-/- mouse develops massive
fibroproliferative atherosclerosis [31]. The increased lipid levels and disease
progression mimic human atherogenesis making the ApoE-I- mouse a desirable
model to study various effects on the cardiovascular system.
Simeonova et al evaluated atherosclerotic plaque formation in arsenic
exposed ApoE-/- mice, and C57BLl6 (background strain), and inflammatory
signaling in human aortic endothelial cell (HAECs) culture [32]. Mice were given
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20 or 100 IJg/mL sodium arsenite in drinking water for up to 24 weeks with either
regular chow or high fat diet. Body weight and serum cholesterol levels did not
significantly differ between arsenic and control animals fed a regular diet,
whereas the high-fat diet significantly increased only cholesterol levels;
moreover, 20 ug/mL sodium arsenite did not increase serum cholesterol or
weight but 100 ug/mL sodium arsenite had a slight but significant increase in
cholesterol. C57BLl6 mice did not develop atherosclerotic lesions with any
exposure or diet; however, mice with 20 or 100 IJg/mL sodium arsenite on high
fat diet induced a 1.6 and 2.3 fold increase in lesion size, respectively.
Inflammatory genes IL-8, NF-kB, and AP-1 were induced in HAECs in response
to arsenic treatment. They also suggest the role of oxidative stress needs further
evaluation as a mechanism for arsenic-related vascular effects. Similar results
were seen by Bunderson et ai, who treated mice with a lower arsenic
concentration (10 ppm) [33]. They also saw a significant increase in plaque size
between arsenic and control, and saw evidence of oxidative stress and
inflammation. These data suggest the ApoE-I- mouse is a good model for
studying the effects of arsenic exposure on atherosclerosis.
Mechanisms of arsenic-induced atherosclerosis
We have already discussed that atherosclerosis is a multifactorial disease
that is characterized by fat accumulation, inflammation, and thrombotic events
[21]. We have also discussed how inflammation is central to every step of
atherogenesis, including initiation, progression, and ultimately the thrombotic
events [22]. Arsenic is a known carcinogen, causing skin, bladder, and lung
11

cancer at concentrations < 150 j.Jg/L arsenic [1-2, 12-15]. Arsenic also has the
noncancer effects of vascular disease, represented as blackfoot disease [17] and
diabetes mellitus[5]. A couple reviews have been published that review
epidemiological evidence implicating arsenic exposure in cardiovascular disease
and atherosclerosis [34-35]. Briefly, these two reviews look not only at the
epidemiological evidence, but also at in vitro cell culture studies and in vivo
ApoE-I- mouse studies. Simeonova et al reviews epidemiological studies on
arsenic exposure from 1989-2004 and examines animal models of
atherosclerosis and arsenic. States et al summarizes several epidemiological
studies in Bangladesh and Taiwan, as well as provides an updated review of
arsenic exposure in the ApoE-I- mouse. Now we look at several studies
implicating arsenic exposure in accelerated atherosclerosis, chronic
inflammation, and cardiovascular disease risk factors such as diabetes mellitus.
A study by Wu et al showed that a high fat diet exacerbates arsenicinduced liver fibrosis in mice [36]. This study exposed Kunming white mice to
water containing 200 ppm arsenic as sodium arsenite for 10 months and
collected blood and livers. They found that arsenite significantly increased serum
aspartate aminotransferase (AST}-a clinical sign of liver injury-levels 5 fold,
and when combined with a high fat diet increased by 10 fold over unexposed
controls. Mild fibrosis (5 fold increase over unexposed controls) occurred in the
arsenite alone group; combined with a high fat diet, however, fibrotic lesions
were more severe (more than 10 fold increase over unexposed controls). RT-

peR was used to reveal an increase in expression of genes related to hepatic
12

inflammatory response, namely TNF-alpha and IL-6 by 6 and 7.5 fold,
respectively, which was drastically increased in a high fat diet. TGF-beta was
also enhanced for a high-fat diet with arsenic exposure (13 fold) and played a
role in arsenic hepatofibrogenesis. A high fat diet enchanced arsenic-induced
liver fibrosis in this study and caused an array of related aberrant gene
expression changes [36]. Arteel et al demonstrated similar results using four to
6 week-old C57BLl6J mice were exposed to 49 ppm arsenic as sodium arsenite
in drinking water for seven months [37]. They showed AL T and AST levels were
significantly increased 2 and 3 fold, respectively in response to
lipopolysaccharide (LPS) challenge. Arsenic pre-exposure in this study
significantly increased liver damage due to LPS. This, combined with a review in
the Waalkes lab, show that the liver is a major target organ of arsenic toxicity and
carcinogenesis [38]. Many of the aberrant genes that were differentially
expressed in these experiments are related to inflammatory signals and that
cause restructuring of the liver.
A study by Srivastava et al shows arsenic exacerbates atherosclerotic
lesion formation and inflammation in ApoE-I- mice [39]. Three-week-old mice
were exposed to arsenic in drinking water at 1, 4.9, and 49 ppm arsenic
concentrations for 13 through 33 weeks. 10 week-old control mice showed few
lesions in aortic arch, while arsenic-exposed mice showed >5 fold larger lesions
(p<O.01). Exposure to arsenic increased plaque formation in the aortic valve and
aortic arch in a dose-dependent manner at 1 and 4.9 ppm arsenic in mice
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exposed for 13 weeks; macrophages also accumulated in lesions in a dosedependent manner.
Various signal transduction pathways are arsenic-induced, and reviews
can be found here [40-41]. The three major classes of MAPKs are extracellular
signal-regulated kinases (ERK)s, c-jun N-terminal kinases (JNK), and p38. ERKs
are growth factor-responsive and induce cell differentiation, proliferation, and
transformation signaling. JNK and p38 primarily mediate cytokines and stressrelated responses such as cell growth arrest and apoptosis. These pathways
affect genes that perform a variety of cellular responses that have mechanisms
leading to cancer-causing effects. Nuclear Factor-kappa B (NF-kB) is a
transcription factor that mediates cellular processes such as cell-to-cell
interaction, intracellular communication, cell recruitment or transmigration,
amplification of pathogenic signals, and initiation or acceleration of
carcinogenesis. MAP kinases playa role in arsenic-incuded NF-kB activation but
are complicated and have been reviewed by Qian et al [40].
There are also reports that in utero (developing fetus in mother) arsenic
exposure induces the early onset of atherosclerosis in ApoE-I- mice [42].
Pregnant mice were exposed to 85 1J9/L sodium arsenite (49 ppm arsenic) in
drinking water for 2 weeks, and the aortic trees of male offspring were analyzed
at 10 and 16 weeks after birth. A few small lesions were seen in unexposed
control mice. Atherosclerotic lesions in the aortic valve were seen in 5 of 10
arsenic-exposed mice, and as a group had 2 fold greater lesion size than
controls (0.5-1.2% in controls vs. 0.6-3.8% in arsenic-exposed; p<0.05). The
14

authors speculate arsenic has lasting effects on susceptibility to atherosclerosis
in adulthood related to endothelial dysfunction [42]. In addition, a study by Fry et
al monitored gene expression profiles in newborns whose mothers were arsenic
exposed during pregnancy and has proposed 11 transcripts that are potential
biomarkers of prenatal arsenic exposure [43]. CXL 1, DUSP1, EGR-1, IER2,
JUNB, MIRN21, OSM, PTGS2, RNF149, SFRS5, and SOC3 all show a dose
response to prenatal arsenic exposure. Stress response and cell cycle
regulation are the associated molecular functions of this gene set. Furthermore,
this study looks at other genes and found that gene networks centered on NF-kB
and IL 1-beta, an inflammation response gene, transcription factors STAT1 and
HIF-1alpha, and proinflammatory cytokine TNF-alpha [43].
Kozul et al found chronic arsenic exposure in drinking water alters immune
response genes expression in mouse lung [44]. Six-week-old C57BLl6J mice
were exposed to 0.010 ppm arsenic as sodium arsenite in chow and 0.010 or
0.100 ppm arsenic as sodium arsenite in drinking water for 5 weeks and RNA
from lung samples were collected for microarray analysis. They saw alterations
in immune-related gene expression using Ingenuity Pathway Analysis (IPA) in
0.010 and 0.100 ppm arsenic exposure. Pathways including TNF-alpha (which
was upregulated) and IL-1ITLR signaling were also altered. This study shows
that even low-to-moderate levels of arsenic are causing aberrant gene
expression using in vivo models.
Arsenic is metabolized in the liver by humans and rodents, and the liver is
a known target of arsenic toxicity causing abnormalities such as fibrosis and
15

hepatocarcinoma The Waalkes lab has published articles elucidating
mechanisms of arsenic-induced liver injury [36, 45] including a literature review
[38]. Among potential mechanisms for arsenic hepatocarcinogenesis are
oxidative damage and stress, altered DNA repair, protein interaction with zinc
finger proteins, hypo- and hypermethylation, and aberrant estrogen linked gene
expression. As mentioned earlier, Arteel et al have studies implicating arsenic
exposure to liver injury [37]. They demonstrated that even subhepatotoxic levels
of arsenic are able to enhance inflammatory liver damage caused by
lipopolysaccharide (LPS) and elicited a hyper-response. These studies suggest
arsenic may be a risk modifying factor for other diseases.
We have proposed a body of evidence (above) linking arsenic exposure
with cardiovascular complications. Cardiovascular disease is prevalent
throughout the world and in the United States. Even a small increase in risk
attributed to arsenic exposure would translate into a large number of excess
deaths and would therefore be of great significance to public health. Providing
insight into the biological mechanisms by which arsenic is able to exacerbate
atherosclerosis may reveal targets for preventative measures or therapies.
Additionally, learning more about the effects of a known water contaminant would
aid policy-making decisions based on risk-cost-benefit models.
We hypothesize that chronic arsenic exposure accelerates atherosclerosis
by disrupting liver homeostasis. Homeostasis in the liver is disrupted in a way
that makes the liver prone to aberrant gene expression changes that result
metabolic dysregulation and inflammation. The inflammation in the liver is able
16

to impact the rest of the body, and thereby atherosclerotic lesions, through
systemic circulation because of the chronic nature of the immune response. The
following study examines the transcriptome of the livers of ApoE-I- mice exposed
to 49 ppm arsenic in drinking-water as sodium arsenite (NaAs0 4 ) from 3 weeks
(PND21) to 10 weeks (PND70) of age.
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CHAPTER 2
METHODS

Animal housing and treatment protocols
Male ApoE-I- mice (B6.129P2_ApoEtm1unc/J, Jackson Laboratory, Bar
Harbor, ME) were used in this study. Mice were housed in pathogen-free
conditions in the University of Louisville vivarium under temperature control in a
12 h lightl12 h dark cycle. All mice were maintained on a normal chow diet and
tap water prior to and during exposure as described previously [42]. Tap water
contains arsenic below the detection limit of 2 ppb, according to the Louisville
Water Company. Arsenic concentration in the normal chow was not measured in
the present study; however, arsenic up to 390 ppb has been reported in nonpurified diet [46]. This study and protocols therein were approved by the
University of Louisville Animal Care and Use Committee.
Three week old mice (PND21) were weaned and maintained on tap water
(control) or tap water supplemented with Sodium Arsenite, NaAs02, (85 mg/L;
49 ppm As; 49 mg/L As) for 7 weeks by Heather Miller. Mice were euthanized
immediately at the end of the exposure period, when they were 10 weeks old
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(PN070). Livers and other organs were collected and snap frozen in liquid
nitrogen and subsequently stored at -80 C until analysis.
RNA collection and preparation
Livers of ApoE-/- mice with or without exposure to 49 ppm arsenic in
drinking-water were collected. RNA was extracted, and sample quality was
checked by A260/A280 ratio. Yulan Piao in Minoru Ko's lab at the National
Institute on Aging (NIA) generated fluorescently-Iabeled double-stranded cONA
using a T7 reverse transcriptase. A reference total mouse standard RNA (Cy5)
was obtained from Stratagene. Labeled samples at the NIA were applied to the
NIA Mouse 44K Microarray v2.1 (Whole Genome 60-mer Oligo) GEO accession
GPL2552, as previously described [47]. Each of the control (Cy5) and
experimental samples (Cy3) were used on one array, for a total of 6 arrays.
Microarray analysis
Microarray output data was processed by the National Institute on Aging
(NIA) and provided in a tab-delimited text file. Data files have been uploaded to
NCBI Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/), and
the GEO accession number is pending approval. The data file contained
numerical Cy3 and Cy5 signal values per chip for each of the probes, which were
represented as proprietary Agilent Feature 10's (also called Probeset 10's or
Probe 10's in some systems). Feature 10's were combined with Agilent
annotation data. The annotation data allowed propriety Feature 10's to be
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identified by open standards, where available, in the form of RefSeq accession,
Genbank accession, Entrez gene symbol, among others.
The signal values were processed by both GeneSpringGX 10 (Agilent
Technologies) and Partek Genomics Suite (Partek Inc.) for comparison. The
process was similar in both programs: We used each program's import feature
on our signal values file, and linked it to the Agilent annotation data. Next we
defined each column of signals as either Cy5 (standard RNA) or Cy3
(experimental sample). Then we formed groups for different experimental
parameters; e.g. treatment conditions (arsenic-exposed and unexposed control)
and age when euthanized (PND70). Finally, we needed to define interpretations
for the data-that is, compare and contrast arsenic-exposed vs. unexposed
control groups. Each program provided various, slightly different statistical
methods to interpret the data. In GeneSpring we used the unpaired TTest of
equal variance, and in Partek we used the ANOVA to obtain p-values-both
GeneSpring and Partek averaged signal value over replicates. Programs were
compared and contrasted (explained in results). Fold-change ratios were
calculated identically in each program by dividing the replicate average Cy3
(experimental samples) by the replicate average Cy5 (standard RNA). Foldchange ratios were log2-transformed into fold-change values that are reported as
either up or down in arsenic-exposed vs. control unexposed.
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MicroRNA microarray analysis
A microRNA microarray analysis was performed by Exiqon using
miRCURYTM LNA Array Version 8.1. Results were provided in a spreadsheet in
Microsoft Excel format with signal values for each probe with Hy3 as arsenicexposed and Hy5 as RNA standard from Ambion. Probes were labeled with
miRNA names that match miRBase 10's. Filtering criteria was based on based
on students t-test used in Microsoft Excel and defined as all micro RNA's where

p:50.05. Those that passed these criteria were subsequently used in further
analysis.
Next, we found mRNA targets to the microRNA. We used two different
targets databases, TargetScan (http://www.targetscan.org/) and microCosm
(http://www.ebi.ac.uklenright-srv/microcosm/htdocs/targets/v51). TargetScan
provides a browser interface for searching each microRNA individually,
outputting matching mRNA in a text file with columns for Entrez gene symbol,
number of conserved sites, and representative microRNA. MicroCosm Targets
provides a tab-delimited text file containing all microRNA-mRNA pairs in a
specified species. Using this, we filtered out genes that were targets of our
microRNA, obtaining a text file with columns corresponding to Entrez gene
symbols and binding characteristics. We filtered these lists down by finding
microRNA-mRNA pairs that were in common between the two lists.
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Functional analysis
Ingenuity Pathway Analysis (IPA; Ingenuity Systems) allows us to gain
insight into the biological significance to our large gene set. IPA takes advantage
of several different data sources including, but not limited to, Argonaute for
microRNA-mRNA interactions, BIND for protein-protein interactions, and Gene
Ontology. We uploaded the entire gene set for each GeneSpring and Partek,
including all annotations and specifically columns for p-value and fold-change.
We used the Genbank Accession number as the identifier to allow IPA to map
additional annotation information. We performed a New Core Analysis with each
set of data where p:S;O.01 with any fold-change (FC); the settings were defaulted
(all databases) with species set to both human and mouse.
DAVID Bioinformatics Resource (Database for Annotation, Visualization
and Integrated Discovery; http://david.abcc.ncifcrf.gov/) is an application that
enhances data analysis in functional annotation. Similar to IPA, DAVID allows us
to extract biological meaning from our large gene set. DAVID uses several
different publicly available tools to create function annotation including, but not
limited to, GoMiner, GSEA, Onto-express. It will then display only the most
significantly enriched terms. We used DAVID according to protocols published in
Nature Protocols [48] and Genome Biology [49]. Both our GeneSpring and
Partek annotated gene sets data were filtered for genes with p:S;O.01 with any
fold-change (FC). DAVID only allows the identifiers-it does not use p-value or
FC information, so we uploaded the filtered Genbank Accession numbers into
DAVID. It automatically detected mouse as our host and set the background
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gene list to the whole mouse genome. The Functional Annotation view was used
to evaluate function based on all databases available in DAVID.
Transcription factor binding sites analysis
We also utilized computational promoter analysis to find significantly enriched
transcription factor binding sites (TFBS) using Expander (EXpression Analyzer
and DisplayER; http://acgt.cs.tau.ac.illexpander/). Expander is a full-featured
suite for genomics analysis. It allows uploading of a raw signal file that takes the
data through processing, normalization, mapping, filtering, and then may perform
a plethora of enrichment-finding procedures-the enrichment-finding is similar to
IPA and DAVID. We, however, are exclusively interested in Expander's promoter
analysis feature. We followed a protocol published in Nature Protocols as a
reference [50]. Expander requires an organism specific data file to provide gene
information, including the transcription factor fingerprint files. The information in
the data file is obtained from publicly available databases such as NCBI,
Ensembl, and others. We used the mouse organism file.
Promoter analysis utilizes the PRIMA algorithm, which works by finding
transcription factors whose binding sites are enriched in a given set of promoters.
To stay within the restraints of the program, we were restricted to looking at a
region 2000 bp (base pairs) upstream and 200 bp downstream of the
transcription start site (TSS) in our genes of interest. We filtered GeneSpring
genes where p:S;0.05 and FCO::±1.5-genes that had a "good chance" of being
"highly differentially regulated" in our gene set. Expander requires genes to be
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identified by Entrez gene 10's. To convert them, we uploaded the Entrez gene
name into DAVID and used the batch name conversion tool to obtain the gene
10's for mouse. We are then able to import the gene set without any expression
values into Expander. Expander returns TFBS names, along with number of
genes enriched with it and a p-value against the total mouse genome as the
background. To relate TFBS to the transcription factor (TF) that binds it, we used
MAPPER (http://snpper.chip.org/mapper/mapper-main) to resolve the TFBS
numerical IDs into most-likely binding TFs.
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CHAPTER 3
RESULTS

Gene expression profiles, using RNA derived from livers of apoE-I- mice
exposed and unexposed to arsenic, were run on the whole-genome mouse NIA
44K 2-color oligo-DNA microarrays. When we began this study, we had to
choose among many resources for analyzing our microarray data, including the
ability to choose between two different genomics suite applications,
GeneSpringGX 10 and Partek Genomics Suite. Both applications provided
comparable features for our needs, so we compared and contrasted how these
applications differed in the processing of our data. Signal files containing raw
Cy5 and Cy3 readings were imported to GeneSpring and Partek as described in
the Materials and Methods. We received the signal files from NIA (materials and
methods), and they had already normalized the data and no further normalization
was necessary. Figure 1 is an MvA plot that shows the difference versus the
average of probe measurements between two samples and assesses the relation
between the Cy5 and Cy3 channels of each hybridization. Each small square
represents an individual probe. The original plot (left) and GeneSpring
normalized plot (right) did not differ, indicating the signal file was already
normalized, as we expected.
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Each of the expression files contained signal values for 41 ,961
oligonucleotide probes. Using NIA annotation file data, probes were mapped to
28,256 (21,484 unique) Entrez gene symbols and 28,225 GenBank (20,686
unique) accessions. Although there were more gene symbols mapped to probes,
when we uploaded the dataset to Ingenuity Pathway Analysis (IPA) we received
over 4000 fewer IPA mapped IDs with the gene symbols set as the 10 column
than with GenBank accessions. Less IPA mapped IDs means that fewer of our
probes, and subsequently fewer of our genes are available for analysis. Since
the GenBank accessions provided more annotation information in IPA than gene
symbols, we subsequently used GenBank accessions for all our functional
analyses.
Significantly expressed genes were identified by TTest in GeneSpring and
by AN OVA in Partek. Fold-change was calculated with log2 transformed
Cy3/Cy5 ratios. For functional analysis we focused primarily on genes passing
the criteria filter p:50.01 with any fold-change. We were primarily concerned with
populating our functional analysis programs with all of the genes that were
significantly regulated, regardless of the amount of change. These sets we
loaded into both IPA and DAVID for comparative analysis.
Comparing and contrasting GeneSpring and Partek
Principal component analysis (PCA) allows a broad overview of how the
data sets relate to each other and is one way to express the variability among the
sets. In Figure 2, we provided a 3D PCA image for both GeneSpring (top) and
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Partek (bottom). The figure contains information for this postnatal study
(exposures: none-pnd70 and pnd21-pnd70) and for a prenatal study (exposures:
none-pnd1, gd8-pnd1, and gd8-pnd70) that was performed at the same time.
Both programs indicate similar groupings among the data sets (similar colors
group together and similar shapes group together). The biggest variability
among the data sets was the age at which the mice were euthanized (called age
at sacrifice), on the x-axis. In GeneSpring the pnd1 group is represented by
squares in the foreground, and in Partek the pnd1 group is isolated on the left
side of the graph. Additionally, including all of the components, there are
groupings among replicate sets; however, the replicates corresponding to no
arsenic exposure (none-pnd1 and none-pnd70) have the greatest spread and
therefore greatest variability.
Both GeneSpring and Partek contain functional analysis abilities similar to
IPA and DAVID; however, these methods were not further explored. GeneSpring
requires different results interpretations to have specific annotation data that was
not available to us in our Agilent annotation data file; for example, GO Analysis in
GeneSpring requires Entrez gene ID's in the form of their Homo sapiens
numerical ID's, which were unavailable because we were using a mouse genome
microarray chip. Partek works similarly; however, we had the additional
drawback of not having direct access to the program at our leisure. The best
course of action was to use the readily available IPA and DAVID applications,
which specialize in functional analysis of gene sets.
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We initially compared the lists generated from GeneSpring and Partek
with filtering criteria where p:50.01 and any fold-change (Fe) by directly
comparing number of probes that were in common between the two programs.
We chose any Fe because both programs computed it similarly, so there was no
difference. After filtering, the lists have 1,461 and 1,346 probes in GeneSpring
and Partek, respectively. To compare these lists, we intersected the two filtered
lists based on the Agilent Feature ID's column. This way, the specific probes
needed to be represented in both lists, eliminating ambiguity accessions or gene
symbols would have created. The intersection produced 599 probes between
GeneSpring and Partek with p:50.01 and any Fe, which is less than half of either
list. This shows that the statistical methods each program uses are not
equivalent, as far as a significance cutoff is concerned; however, this does not
give any insight as to whether this relates to a biological difference in the two
sets. To determine if the two sets differ in function, we will need to use our
functional analysis programs IPA and DAVID.
Ingenuity Pathway Analysis (IPA) functional analysis
We uploaded the GeneSpring and Partek gene set lists into IPA.
GenBank accessions were marked as the 10 field that IPA uses to map genes to
additional annotation data, such as gene function and protein location in the cell.
IPA also accepts the data corresponding to the p-value and fold-change (Fe) of
each gene. IPA was able to map 27,174 (non-unique) probes on each data set,
which is nearly all of the probes available with GenBank accessions. We ran a
new core analysis on each dataset with criteria set to p:50.01 and any Fe. With
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these settings, IPA reported having 775 molecules available for
functions/pathways and 374 networks eligible for GeneSpring and 690 molecules
for functions/pathways and 324 network eligible for Partek. After running the
core analysis on both datasets, we used the comparison analysis feature to
compare information from both datasets at the same time. The top function in
common between the two was cardiovascular disease. Top canonical pathways
are oxidative phosphorylation and mitochondrial dysfunction. Taking a look at
the networks in the comparison revealed numerous overlaps among genes.
The comparison analysis provides an overlapping networks view where
we are able to view what networks are connected within and between analyses
and how many molecules are in each overlap. Out of 50 networks between both
analyses, only 4 were orphans (not connected to any other network). Many of
the networks contained overlaps that accounted for a third of the network
composition. For example, Figure 3 shows the top 2 networks from each
analysis merged. Both networks have 10 molecule overlaps and are highlighted
in the figure-the top network contains 2 networks composed of 32 molecules
and 28 molecules for GeneSpring and Partek analyses, respectively, and the
bottom 2 networks are composed of 27 molecules each. The top networks
overlap on and contain network hubs on Creb, ERK1/2, GSTM3, GSTM4, MBD2,
PPARG, among others, and the bottom networks overlap and contain hubs on
INF Beta, Interferon alpha, Jnk, MAP2K6, NFkB, MAPK14 (P38 MAPK), among
others. Top functions in the top network are cellular development, growth,
proliferation, and movement, connective tissue development and function,
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embryonic development, and cell cycle. Top functions in the bottom network are
cellular movement, hematological system development, function, and disease,
immune cell trafficking, cell death, and post-translational modification. The top
network functions and top pathways are listed in Table 1 and Table 2,
respectively. Finally, the "Top Tox functions" (toxicity phenotypes and clinical
pathologies) for both datasets are mitochondrial dysfunction, oxidative stress,
and LPS/IL-1 mediated inhibition of RXR function. These results indicate that
both lists have common biological functions, despite having less than half the
significantly regulated probes in common.
DAVID functional analysis
We corroborated results obtained in IPA by using DAVID Bioinformatics
Resource. DAVID does not accept p-value or FC. In that respect, DAVID
exclusively performs enrichment analysis-it only finds functions and/or networks
that are significantly overrepresented by our gene list over a background gene
list. Each of our gene sets was filtered in Microsoft Excel where pSO.01 with any
FC and output in text-only format containing only GenBank accessions. DAVID
was able to find annotation data for 1026 and 949 GeneSpring and Partek
probes, respectively.

We set total mouse genome as the background gene list.

The next step is to run the functional annotation clustering analysis and view the
combined view. This list is composed of various clusters, arranged by function
and score, containing categories that are database names and terms
represented by short descriptions of the function/pathway that is enriched,
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followed by various statistical measurements including number of molecules
found in the term, percent of term filled, p-value, among others.
Table 3 lists representative terms per cluster for each GeneSpring (A) and
Partek (8). Comparing the tables from each dataset, both lists contain similar
terms that are significantly enriched including mitochondrion, translation, and
ribosome function enrichment. In contrast, the Partek list contains much lower
enrichment scores and lower enrichment percentages, although the values are
still statistically significant (p:50.01). The top functions in the DAVID analysis also
matches what was seen in the IPA analysis. For example, the mitochondrion
term in DAVID matches with the mitochondrial dysfunction and oxidative
phosphorylation with oxidative stress. Additionally, several of the genes that
appear in corresponding pathways from IPA and DAVID overlap Table 4,
showing that the enrichment is due to the same genes and same functional
pathway being enriched by both applications. This overlap lends evidence for
taking a deeper look at these corroborated pathways and how they are regulated.
Additionally, it implicates the mitochondrion in and provides a list of genes for
mitochondrial dysfunction and oxidative phosphorylation.
MicroRNA analysis
MicroRNA analysis revealed a different challenge in differential expression
analysis. The Exiqon microRNA microarray contained only 496 probes, of which
only 344 had readable signals, which is substantially fewer probes than the
cDNA microarray. We performed students t-test in Microsoft Excel on the
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readable signals and were left with 8 probes where pSO.05 and any Fe.
However, of these only 4 microRNA probes had annotation data to continue
analysis, which were mmu-miR-206, mmu-miR-18, mmu-miR-140, and mmumiR-337. We were then interested in what regulatory networks these microRNAs
were most likely to regulate. To do this, we found all of the gene targets for each
microRNA, but we found there are many different databases that provide
prediction of micro RNA targets and compared two popular methods, miRBase
(http://www.mirbase.org/) and TargetScan (http://www.targetscan.org/).
There are fundamental differences in how each micro RNA target
prediction algorithm works. As a result, the predicted genes vary widely between
miRBase and TargetScan Table 5. TargetScan produced substantially fewer
predicted target genes in general-761 genes with TargetScan vs. 3912 genes
with miRBase total. Additionally, the overlap or intersection between the two
gene lists was low, resulting in 175 total genes that were common between the
two methods for the 4 microRNAs. The mmu-miR-337 did not have any
predicted genes in either database at the time of analysis.
Using the gene set of the intersection between miRBase and TargetScan,
and we ran it through the same paces as our original transcript gene sets-we
used IPA and DAVID to lend insight into the biological workings of the genes
predicted to be targeted by our Significantly expressed microRNA. IPA analysis
revealed networks in Figure 4 with top functions tissue morphology, cellular
growth and proliferation, and gene expression for network 1 (top) and cancer, cell
morphology, and DNA replication, recombination, and repair for network 2
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(bottom). Notable genes in these networks include TNF, which is a hub in
networks, TP53, HIF1A, and many other DNA binding transcription factors, and
IL 10 in network 1. DAVID analysis reveals several different functional groups
significantly enriched with the microRNA targets gene set. Additionally, top
canonical pathways are listed as RAR activation, aryl hydrocarbon receptor
signaling, role of BRCA 1 in DNA damage response, estrogen receptor signaling,
and hypoxia signaling in cardiovascular system. Listed in Table 6 are functions
significantly enriched by this gene set. Listed in the table are many functions
related to transcriptional regulatory networks, including the term transcriptional
regulation and DNA binding. If the predicted genes targeted by the microRNAs
that were Significantly involved in our system were involved in regulatory
networks such as transcriptional regulation, we may see these results
corroborated with a transcription factor binding site enrichment analysis.
We also wanted to find out how the micro RNA predicted targets compared
to our transcript genes. So, we intersected the miRBase and TargetScan
intersection genes (175 genes) with all genes where p:S;O.01 and any FC (1461
genes). This intersection resulted in only 8 unique genes that are similar
between the two lists, and they are Mylk, Mfn1, Pgrmc1, Commd2, E2f5, Usp33,
Dhx15, and Pdap1. These are not enough to populate enriched pathways or to
construct networks, so we had to use a relaxed filtering method. We then looked
at microRNA predicted target genes from miRBase (3912 genes) and intersected
those with our filtered genes where p:S;O.01 and any FC (1461 genes). This
intersection resulted in 158 unique genes. We ran this set through IPA to find if
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any networks were populated and found results similar to what we saw in our
transcript gene set Figure 5. The top 2 networks report functions for cell death,
hematological system development and function, and inflammatory disease (top)
and cellular development, cell death, and cell signaling (bottom). The networks
had hubs at TNF, JNK, and p38 MAPK (top) and TNF, IL 1B, STAT1, STAT3, and
SOCS3 (bottom).
Transcription Factor Binding Sites (TFBS) analysis
Initially, we ran our TFBS enrichment analysis with all of the genes from
our IPA/DAVID analysis set (where pSO.01 with any FC). However, this resulted
in hundreds of TFBS that were only marginally enriched (data not shown). We
decided to be more selective with the dataset we input and decided to check only
transcripts that were likely to be significantly involved with a large change against
control, so we filtered the genes where pSO.05 and

FC~11.51

which resulted in 94

genes passing the criteria. In Table 7 are listed the most significantly enriched
transcription factor binding sites, along with the transcription factor that binds the
site and the fold-change of the TF, if it was available in our original gene data.
Only a few of the transcription factors that were resolved from the TFBS were
differentially expressed, indicated by our transcript dataset-Bhlhe40, Prdm1,
Pparg, Zcrb, and Gtf2a1 were changed by at least 1.1 fold up or down.
Additionally, Figure 6 is a hierarchical cluster map showing each gene and the
TFBS it contains. With this, we are able to look at specific genes in relation to
transcription factor regulation and identify sets of genes with potential common
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regulators. Thus, sets of potentially coordinately regulated genes can be readily
identified.

35

CHAPTER 4

DISCUSSION

Arsenic in drinking-water is a worldwide health problem, and millions of
people are exposed to the detrimental effects of chronic arsenic exposure with
drinking water levels exceeding the US EPA and WHO guidelines [2]. Arsenic
exposure in human populations is associated with long-term health
consequences [51]. We would like to address the molecular mechanisms
pertinent to arsenic-induced cardiovascular disease. In this study, we
characterize transcription-based molecular events occurring in the liver that may
impact and contribute to the acceleration of atherosclerosis in the vascular
system.
The current study shows chronic arsenic exposure in drinking-water
induced gene expression changes in the liver of apolipoproteinE-knockout
(ApoE-I-) mice related to functions dealing with metabolism and inflammation
response. This study is an extension of one previously done in our lab where we
observed chronic arsenic exposure in drinking water exacerbates atherosclerosis
in ApoE-I- mice [39], and was discussed in a review [35]. Using an inbred mouse
model provides us a way to eliminate many variables associated with population-
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based arsenic exposure studies-it also reduces confounding factors that may
occur in genome-wide expression studies.
In this study, we evaluated the effects of arsenic exposure on gene
expression in livers of ApoE-I- mice. GO categories in DAVID found to be
enriched with significantly differentially expressed genes between arsenicexposed and unexposed groups included broad terms such as mitochondrion,
translation, and ribosome function. Additionally, Ingenuity Pathway Analysis
(IPA) produced networks with functions for cellular development, cellular growth,
cellular proliferation, and cellular movement, cell cycle, hematological system
development, hematological system function, and hematological system disease,
immune cell trafficking, and post-translational modification that contained hubs
on Creb, ERK1/2, GSTM3 and GSTM4, MBD2, and PPARG for one network and
INF Beta, Interferon alpha, Jnk, MAP2K6, NFkB, and MAPK14 (P38 MAPK) on
another network. These genes play an important role in mitochondrial function
and inflammation regulation. Additionally, we included microRNA data into this
study. There is much that is not known about the functions of microRNA,
especially those found in the mouse. However, we were able to use predictive
techniques to shed some light on the processes occurring here. In general,
microRNA pointed to broad functions such as biological regulation, transcription
regulatory activity, and blood vessel morphogenesis that support their supposed
functions. Gene alterations seen in the present study are largely consistent with
previous analyses in gene expression on arsenic in drinking water [33,36,43-45,
52]. Below is a critical discussion of the information contained in the results.
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Atherosclerosis develops in "steps," when the conditions are present in a
way to promote atherogenesis. We have previously discussed diseases such as
diabetes [20], obesity [19, 27, 53], nonalcoholic fatty liver disease (NAFLD) [26],
and chronic inflammation [28], among others that contribute to the risk
atherosclerosis and cardiovascular disease. We propose that chronic arsenic
exposure predisposes the mice to atherosclerosis when they are exposed to a
second atherogenic insult, such as high fat diet or infection, if not directly.
The first and most significantly enriched functional Gene Ontology (GO)
category in our gene set is the mitochondrion term. The mitochondrion
(mitochondria, plural) is an organelle responsible for aerobic tissue respiration
and is the primary site for energy production in eukaryotic cells via the electron
transport chain. Oxidation of glucose takes place to produce energy in the form
of adenosine triphosphate (ATP) in a process called oxidative phosphorylation. It
is likely not a coincidence we also observed the oxidative phosphorylation GO
term to be significantly enriched. Mitochondrial oxidative phosphorylation
(OXPHOS) dysfunction leads to oxidative stress and is associated with
atherogenesis and cardiac failure [54]. Although these processes are occurring
in the liver, it is likely that arsenic reaching other tissues, such as the heart or
vascular tissue, will show similar disruptions in oxidative phosphorylation.
Additionally, the mitochondrion is responsible for a plethora of other processes,
including signaling, cellular differentiation, cell death, and cell cycle control.
Our data also indicate that mitochondrial dysfunction and oxidative stress
are occurring. It is not surprising that these two processes pop up at the same
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time given that mitochondria are the primary consumers of oxygen, containing
many redox enzymes capable of generating reactive oxygen species (ROS) [55].
ROS are chemically-reactive, highly reactive molecules containing oxygen that
also contains an unpaired valence shell electron. ROS is a natural byproduct of
respiration (metabolism of oxygen) but also can be dramatically increased during
times of environmental stress, e.g. ultraviolet (UV) light, and ionizing radiation.
Accumulation of ROS results in oxidative stress. Since the cell is exposed
regularly to ROS, there are defense systems in the form of antioxidants.
Enzymes such as superoxide dismutase (SOD) and glutathione S-transferase
(GST) and small molecules such as ascorbic acid, glutathione, and sulfur
containing molecules will prevent ROS damage by scavenging free radicals,
leaving little net ROS production. If mitochondrial damage occurs with a
decrease in antioxidant defense capacity, there will be net ROS production. If
enough ROS accumulates to trigger oxidative stress it will result in additional
damage to the mitochondria. Once this occurs, a vicious cycle can ensue,
causing even more damage to the mitochondria and further reduce antioxidant
capacity. In this study, many genes of interest related to antioxidant defense
(S002 and various GSTs) are up-regulated, suggesting the livers of arsenicexposed mice are experiencing increased ROS levels. This was expected,
because arsenic is known to produce oxidative stress as a mechanism of
hepatotoxicity, and possibly, carcinogenesis [1-2].
Above we spoke briefly on various arsenic-induced signal transduction
pathways such as mitogen-activated protein kinase (MAPK) pathways that
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regulate the expression of a variety of genes that mediate cell apoptosis,
differentiation, proliferation, and transformation, and Nuclear Factor-kappa B
(NF-kB) that mediates cellular processes such as cell-to-cell interaction,
intracellular communication, cell recruitment or transmigration, amplification of
pathogenic signals, and initiation or acceleration of carcinogenesis. The three
major classes of MAPKs are enriched in our IPA networks, including extracellular
signal-regulated kinases (ERK)s, c-jun N-terminal kinases (JNK), and p38.
Oxidative stress is able to activate p38, which leads to cardiac dysfunctions, via
generation of malondialdehyde [56]. Gosh et al have shown that arsenic not only
increased phosphorylation of MAP kinases p38 and JNK, but they, in turn,
activated NF-kB via the IKK pathway [30]. We have also seen enrichment of the
ERK1/2 network with arsenic exposure. These relate directly with the enriched
network functions dealing with cellular development, cellular growth, and cellular
movement, cell death, immune cell trafficking, among others.
Peroxisome-proliferator activated receptor gamma (PPARG) is a
transcription factor that plays a critical role with lipids in inflammation and insulin
resistance [28]. PPARG can be activated through Creb and ERK1/2 and we see
this association enriched in our networks. Most notably of PPARG actions,
ligands to all PPAR family members suppress production of proinflammatory
cytokines through suppression of NF-kB. It could be that these enriched
networks are compensatory mechanisms to inflammation or damage in the liver.
In that sense, then, arsenic is working upstream of these signals. Indeed, in the
IPA network, PPARG appears to be downstream of the MAP kinase, ERK1/2.
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-----------------------------------------------

Additionally, PPARG is regulated by Myc, which is seen to have enrichment in
the transcription factor binding site analysis. A constant, if slight, elevation of
PPARG may have wide-reaching effects on the liver because of PPARG
transcription factor activity. Indeed, in our dataset we saw that the PPARG
binding site was significantly enriched in significantly differentially expressed
(p:S;O.05 and FC>11.51) genes. PPARG is able to interact with some of our most
highly-regulated genes, so it may be exerting substantial effects in our arsenicexposed livers.
In addition to the molecular mechanisms above, it is beneficial not to
forget the forest for the trees. There are many other risk factors associated with
arsenic-induced atherosclerosis that may not be explained explicitly by our liver
transcriptome analysis, but are supported by some of the pathways that are
enriched. For example, we have seen arsenic affects normal mitochondrial
functions. Mitochondrial dysfunction has been implicated in a number of
diseases including neurodegenerative disorders [55]. cardiovascular disease,
and diabetes [5, 28]. Lane et al have also stated, "Mitochondrial deficiency can
theoretically give rise to any symptom, in any organ, at any age" [57]. Indeed, it
makes sense considering the important functions the mitochondria provide to
eukaryotic cells. Hotamisligil reviewed literature on inflammation and metabolic
disorders and showed these two can be triggered by excess of lipids and glucose
and that the inflammatory response can trigger further metabolic dysfunction,
creating a vicious cycle. Arsenic could be slightly stimulating both of these
pathways, as we have seen. In that case, it would only require a small, chronic
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amount before the system began to propagate the aberrant activity on itself. This
is corroborated with the fact that ROS will activate JNK, discussed above,
causing stress to the endoplasmic reticulum, critical in initiation of inflammation
and insulin action in obesity and diabetes. Hotamisligil discusses therapeutic
targets to manipulate metabolic and immune systems by targeting not single
molecules but networks such as those governed by JNK or even to target
organelles, specifically the mitochondrion. It seems likely that such a
multifactorial disease process brought on by arsenic as we have seen here would
have to be treated at a network level, rather than at single genes.
We worked to minimize limitations and confounding factors in this study by
using a well-established mouse model [35] and treatment protocol [39].
However, transcript levels can vary greatly from one animal to another [46].
Normalization cannot fix all of these problems, and for that reason we used data
that met significance criteria (p:S;;0.01 or 0.05) to be sure there was consistency
across replicates and only real changes were taken into consideration.
Additionally, there have been reports that microarrays dilute levels of gene
expression changes when compared to gene-specific quantitative RT -peR
methods, although directionality seems to remain [44]. Tools such as IPA and
DAVID are crucial in experiments that contain whole-transcriptome information.
They allow researchers to use large gene sets to get insight into modeling,
analyzing, and understanding complex biological systems that would be
impossible by looking at single genes. The microRNA provided a unique
challenge because the data we could collect for analysis was purely based on
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computational predictions [58]. There are many databases based on different
algorithms that provide predicted microRNA targets, however the two very
popular options we chose only overlapped on a few genes. Once the genes are
selected, what to do with them creates another problem because the large sets
of seemingly unrelated genes have to have a meaning attached. The TFBS was
also limited in that it does not report all transcription factors that are significantly
enriched in a gene set of interest. TFBS looks at the nucleotide sequence
present in the region 2000 base-pairs upstream and 200 base-pairs downstream
of the transcription start site. Transcription factors that contribute to a gene may
be tens of thousands of nucleotides up- or downstream of the transcription start
site. However, the TFBS analysis does allow us to see another level of biological
activity that a transcriptome analysis is not able to provide. That is, the
transcription factors in our list mostly do not have any fold-changes associated.
This is not surprising, since many transcription factors are activated through posttranslational modification, such as phosphorylation (as in the case of targets of
MAP kinases such as ERK, JNK, and p38). Using this technique, we were able
to extend the amount of information we are able to obtain beyond that purely
related to the transcript measurements.
This study may have implications on human health, as well. Although
concentrations of arsenic in drinking water was much higher than current EPA
and WHO standards (0.010 ppm), our lab has performed dose-response studies
of arsenic in drinking water to atherosclerosis development and found it to hold
true for exposures as low as 1 ppm to 4.9 ppm, suggesting the effect may scale
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down to lower concentrations. In fact, it has already been proposed that there is
no threshold for effect for noncancer diseases in arsenic exposure [1-2]. This
may be because even small levels of arsenic causing small changes in gene
expression over a long period of time may result in significant structural and
functional changes in the liver. Arsenic may also be acting to "prime" the liver for
an exaggerated reaction to a second atherosclerotic event, such as a high fat
diet or an infection.
Future directions
The results in this study give a broad-view of changes taking place on the
transcript-level. It is important to keep in mind that transcript levels do not have
direct effects on cellular actions, protein drive cellular activity. This should be
taken into consideration when proposing future directions, as these results only
hint at mechanisms taking place in a cell.
The next steps for this study should be to verify inferences that have been
made. The mitochondrion is implicated in dysfunction as well as dysregulation of
oxidative phosophorylation. Experiments focusing on these elements would
clarify whether or not these are occurring. Reactive oxygen species are likely
culprits of problems to the mitochondrion and should also be checked. We
mentioned the effects from arsenic that we have seen may only be small
changes and may actually require another stimulus in order to trigger noticeable
effects. In this way, experiments could be done for mock infections, possibly
using lipopolysaccharides (LPS) and then metrics corresponding to mitochondrial

44

dysfunction should be analyzed. In any case, direct reactions of the
mitochondrion organelle should be a good place to start before concentrating on
more specific areas, such as signaling pathways.
Networks composed of significantly expressed genes contained hubs on
MAP kinase signaling complexes such as ERK, JNK, and p38. These are stressresponse genes and are able to regulate gene expression, cell differentiation,
and apoptosis, and their action may be causing aberrant gene expression in the
liver. These genes are activated through phosphorylation pathways, which would
explain why we did not see their transcript level significantly differentially
expressed. Since we are not able to see direct changes, western blots may be
performed to check levels of phosphorylated proteins to assess activation.
Additionally, we have seen increases in gene expression in genes such as
PPARG, which are regulated by these MAP kinases. Transcript levels should be
confirmed by protein levels in order to validate that the changes seen directly
impact enzymes driving cellular actions.
Conclusion and summary
In summary, we have characterized gene expression changes occurring in
the liver of ApoE-/- mice with arsenic exposure in drinking water. These results
support the hypothesis that chronic arsenic exposure is able to disrupt liver
homeostasis and cause aberrant gene changes. Among the changes, metabolic
functions, especially those in dealing with the electron transport chain, appear to
be disrupted, and the evidence pOints towards an induction of oxidative stress
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that acts as both cause and effect in the dysregulation. This study suggests a
few mechanisms that are disrupting the liver in a way to promote atherosclerosis
in the vascular system and suggests approaches and mechanisms for further
research.
To date, there are still millions of people consuming water that exceeds
50 IJg/L arsenic and possibly twice as many consuming 10 IJg/L arsenic in many
parts of the world [51]. The association between chronic arsenic exposure and
atherosclerosis has far-reaching implications in research and public health.
Because atherosclerosis is a major public health concern, the consequences of a
causal association with arsenic would affect large numbers of people worldwide.
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Figure 1: MvA plot on gene expression. Normalized MA plot of postnatal
arsenic exposure shows no change after normalization , indicating the signal
value data was previously normalized . (Left) is the original MvA plot. (Right) is
the GeneSpring-normalized MvA plot. This plot shows the difference versus the
average of probe measurements between two samples and assesses the relation
between the Cy5 and Cy3 channels of each hybridization . Each small square
represents an individual probe.
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Figure 2: peA analysis on gene expression. Principal Components Analyses
(PCA) comparison for GeneSpring (top) and Partek (bottom) indicates similar
grouping patterns among conditions. These are 3D PCA image for both
GeneSpring (top) and Partek (bottom). Depicted above are two studies, a
postnatal study (exposures: none-pnd70 and pnd21-pnd70) and a prenatal study
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(exposures: none-pnd1, gd8-pnd1, and gd8-pnd70) that were performed at the
same time. Similar colors indicate replicate samples (3 per color).
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Figure 3: IPA networks on gene expression. Merged IPA networks
comparing GeneSpring and Partek data indicate similarities between networks.
(Top) The top functions of this network are cellular development, growth,
proliferation, and movement, connective tissue development and function, and
cell cycle. (Bottom) The top functions of this network are hematological system
development, function, and disease, cellular movement, cellular movement,
immune cell trafficking, cell death, and post-translational modification. Gene
symbols are located in the center of each box; green shapes indicate downregulated genes, and red shapes indicate up-regulated genes, compared with
control. Gray shapes indicate genes that IPA inserted to obtain the most
connections within the network, but are not regulated significantly regulated by
the experiment. Highlighted shapes indicate those that were common between
the merged GeneSpring and Partek networks in the comparison.
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10
Analysis
1-G

1-P

2-P

2-G

3-G

3-P

4-G

4-P

Molecules in Network

Score

ABCB1B, ARHGEF9, ATP51, BRCA1, CA2,
COX6C, Creb, DPP4, DUSP6, EDN2, ERK1/2, F2R,
FOPS, FOXC2, GAPDH (includes EG:14433),
GSTM4, GSTM3 (includes EG:2947), KPTN,
MATN4, MBD2, MED16, MED23, MED26, MSX2,
NDUFB5, PEPD, PL TP, PPARG, PSENEN, RBBP7,
RDBP, RNA polymerase II, SERPINE2, SLC9A8,
UCK1
AFP, AGK, ANK3, ATPIF1, AXL, CDK14, Creb,
DPP4, EDN2, ERK1/2, FDX1, FDXR, FSH, GSTM4,
GSTM3 (includes EG:2947), hCG, Histone h3,
HNRNPK, KPTN, Lh, MBD2, MSX2, MTOR, MYH14,
NPC2, PITX2, PLAUR, PP2A, PPARG, PTTG1,
RGS16, RNASEH2A, SC4MOL, STC1, TFPI2
ACACB, ADIPOO, Akt, CCL22, CCND3, CSF2RB,
CSNK2A1, DHCR24, FCGR2B, GPX4, GSK3B,
HDL, IFN Beta, IGBP1, Interferon alpha, Jnk,
LAMA3, LARGE, LBP, LOC643751, MAP2K6, MIF,
MMP3, NFkB (complex), NLRP2, P38 MAPK, PL TP,
Ppp2c, PRKAA2, PRKCD, RAC1, RPL23A, SSRP1,
TNFRSF9, TNFSF12
ALOX12, BCR, C140RF153, CCND3, CD47,
CDK1, Cytochrome c, EEF1A1, G protein alpha,
GAS6, GDF15, GH1, GPX4, HMGB1L 1, IFIH1, IFN
Beta, IL 12 (complex), Interferon alpha, Jnk,
MAP2K1, MAP2K6, NFkB (complex), NLRP2, OAS1,
P38 MAPK, PNKD (includes EG:25953), SLC16A6,
SMAD3, SOD2, THY1, TNFRSF9, TRAF2, TRIM69,
VDAC1, VPS28
ALPL, ATP9A, ATPIF1, BAG1, BMYC, DHPS, E2f,
EXOSC8, FDX1, FSH, hCG, Histone h3, HRAS, Lh,
MAP2K1, MBD2, NOL3, NPC2, PGRMC1,
PRKAR1A, RAB14, RPA3, SGK1, SKA2, SMAD6,
SMC2, SNRPC, SSRP1, STC1, SUPT16H, TK1,
TMEM126A, TRIB1, TYMS, UXT
AMPK, AP2M1, C140RF166, CYP2A6, CYP7A1,
DLAT, EIF3F, GFER, GLl1, HNF4A, IRS2, ME1,
NCOA1, NDUFS1, NDUFV2, NONO, NROB2,
NR1H4, NR113, NR5A2, PCK1, PPARGC1A, RARA,
RBM3,RPS5,RPS19,RPSA,RXRA,SAT1,SFPO,
SULT1C3, SYNCRIP, THRB, TUFM, UCP3
AIFM1, ATOX1, BAK1, BAX, BMP6, CHMP1A,
DMPK, DNM1L, EIF4E, GRB2, LAT, LAX 1,
LETMD1, LSM1, MAP7, MCM6, MFN1, MFN2,
MPV17, NOP10, PA2G4, PARP1, PCNA, POLD1,
POLDIP2, PPIA (includes EG:268373), RPL 11,
RPL30, RPL 18A, SOS2, STOML2, TALD01,
TNFSF10,YY1,ZNF143
ABCA1, ABCC3, ADIPOO, AEBP1, AKT2, ALB,
BBC3, C5, CCL27, CD36, CETP, CFD, CR1,
CX3CL 1, Cytochrome c oxidase, DIABLO, FOXC2,
HEXA, HEXB, HMGB1L 1, IL27, LAMB3, LPL,
MFHAS1, MUT, NR112, PPARG, PRODH, PSMB10,
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Top Functions

37

Focus
Molec.
32

31

28

Cellular Growth and
Proliferation,
Cellular Movement,
Cell Cycle

29

27

Cellular Movement,
Hematological
System
Development and
Function, Immune
Cell Trafficking

27

27

Cell Death,
Hematological
Disease, PostTranslational
Modification

21

23

Embryonic
Development,
Tissue
Development, Cell
Death

15

18

Gene Expression,
Lipid Metabolism,
Small Molecule
Biochemistry

19

22

Cellular
Compromise,
Cellular Assembly
and Organization,
Cell Morphology

13

17

Lipid Metabolism,
Molecular
Transport, Small
Molecule
Biochemistry

Cellular
Development,
Connective Tissue
Development and
Function, Embryonic
Development

5-G

PTGES,PTPN12,SCNN1G,SLC01A2,TNF,UCK1
APP, ARC, ATP5A1, ATP5C1, ATP50, CAMK2A,
CSNK1G2, DLG4, DSTN, FMR1, GLUL, GRIA1,
GRIA2, GRIK5, HTT, INS, LEP, NRXN1, PHB2,
PHLPP1, PRDX1, PRDX2, PRDX3, SDHA, SIK1,
SLC25A6, SRXN1, SUCLA2, SYT1, VDAC2

14

17

Cell-To-Cell
Signaling and
Interaction, Nervous
System
Development and
Function, Cell
Morphology
Inflammatory
Response, Cell-ToCell Signaling and
Interaction,
Hematological
System
Development and
Function
Free Radical
Scavenging,
Cellular Movement,
Genetic Disorder

5-P

ACTG1, Actin, ADH5 (includes EG:128), APP,
AVPI1, BLVRA, C5AR1, CCL5, CD163, CHN2,
COPS5, CXCL3, CYBB, DUSP10, FAM38A, FEZ1,
FMR1, IFNAR1, IL 13, ITM2B, Lamin b, LDL, MIF,
MSN, NOS2, PITRM1, PLEC, RAC1, RIPK2, SNCA,
SORT1, SPINT2, TNFRSF1A, TPMT, VPS35

13

17

6-G

APH 1A (includes EG:511 07), BIRC2, CA3, CELA 1,
CER1, CSNK2A1, CTNNB1, DHX15, DPAGT1,
EGF, GNA11, GPI, ICAM2, IFNG, IGBP1, IRAK4,
ITGB2, KLK2, NFkB (complex), PCSK6, P13,
PIK3CG, POLR2F, PRPF8, PSEN1, PTEN, RAC1,
RPS6KB1, RPS6KB2, SERPINA3, SMNDC1, SOD2,
TLR5, TNFRSF1B, TXN2
ABCB1B, BRCA1, CAV1, CCNA2, CCNB1, CCND3,
CDK1, CDKN1A, CEBPA, CL TC, DHFR, DNTT,
ERCC1, GDF15, GMNN, GSTM1, GSTM5,
LETMD1, MCM6, MCM7, NANOG, NR112, PHC1,
POU5F1, PPARG, RB1CC1, SNX9 (includes
EG:51429), STUB1, STX8, TOM1 L 1, TOPBP1,
TP53, TSG101, WWTR1, XRCC5
AACS, AKT1, ANXA11, ATP5F1, BCL 10, CARTPT,
CCL3L3, CCND3, CLEC7A, CRYL 1, CSNK1E,
CYP7A1, DLAT, EGF, EIF6, HTR4, IGFBP2, IKBKG,
IL2, IMPDH2, LEP, ME1, MEP1A, MIR122A, N-cor,
NDUFS1, NDUFV2, NFATC1, PER1, PER2,
PPARGC1A, RPS6KB1, SLC27A5, THRB, THRSP
ACTL6A, AK3, AKT2, ANXA6, ARID1A, BAF110,
CA2, ETS2, FCGR2B, GCAT, GLlPR2, IF130, IL4,
IL5, KLHDC2, MMP1 (includes EG:4312), PDK1,
PGM1, PLlN2, PPARG, RHAG, RHCE, SEMA4A,
SLC4A1, SMARCA4, SMARCB1, SMARCC1,
SMARCC2 (includes EG:6601), SMARCE1, ST?,
TADA2B, TEP1, TERT, THY1, TMEM97

12

17

12

16

Cell Cycle, Cancer,
Reproductive
System Disease

12

17

Genetic Disorder,
Metabolic Disease,
Behavior

12

16

Gene Expression,
Cellular Assembly
and Organization,
Cellular
Compromise

6-P

7-G

7-P

Table 1: Top IPA networks for GeneSpring and Partek. Table shows network
ID, genes in network from list, number of genes, network score, and top functions
of network. Network ID and analysis indicated for GeneSpring (G) and Partek
(P).
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Ingenuity Canonical
Pathways
Oxidative Phosphorylation

Analysis

Molecules

GeneSpring

Oxidative Phosphorylation

Partek

Mitochondrial Dysfunction

GeneSpring

Mitochondrial Dysfunction

Partek

Ubiquinone Biosynthesis

GeneSpring

Ubiquinone Biosynthesis

Partek

Citrate Cycle

GeneSpring

Citrate Cycle
Protein Ubiquitination
Pathway

Partek
GeneSpring

Protein Ubiquitination
Pathway

Partek

Butanoate Metabolism

GeneSpring

Butanoate Metabolism

Partek

Propanoate Metabolism

GeneSpring

Propanoate Metabolism

Partek

NDUFA4, SDHB, UQCR11, TCIRG1, NDUFB5,
COX5B, UQCRB, ATP5G2, NDUFB10, NDUFB9,
NDUFA5, NDUFS1, ATP6V1F, NDUFC2, ATP5G1,
ATP5H (includes EG:10476), ATP5J2, ATP5F1,
ATP51, COX7C (includes EG:1350), COX411,
NDUFS4, ETNK2, NDUFA8, SDHA, ATP5J,
NDUFV1, NDUFC1, COX7A2, COX6B1, ATP50,
NDUFS7, ATP5A1, COX6C, ATP6V1A, NDUFS3,
ATP5C1, UQCR10, NDUFV2, NDUFS8, PPA2,
UQCRC2, NDUFA7
SDHA, ATP5C1, NDUFS1, NDUFV2, NDUFS8,
PPA2, TCIRG1, UQCRC2, ATP6V1G1, NDUFS3
NDUFA4, SDHB, NDUFB5, COX5B, PSENEN,
UQCRB, NDUFB10, NDUFB9, NDUFA5, NDUFS1,
SOD2, GPX4, COX7C (includes EG:1350),
COX411, NDUFS4, AIFM1, NDUFA8, SDHA,
ATP5J, NDUFV1, COX7A2, COX6B1, NDUFS7,
COX6C, ATP5A1, NDUFS3, APH1A (includes
EG:51107), ATP5C1, PRDX3, NDUFS8, NDUFV2,
TXN2, UQCRC2, TXNRD2, NDUFA7
SDHA, NDUFAF1, NDUFS3, GPX7, APH1A
(includes EG:51107), ATP5C1, NDUFS1, PRDX3,
NDUFV2, NDUFS8, UQCRC2, MAPK10, GPX4,
TXNRD2, AIFM1
NDUFA4, NDUFC1, NDUFV1, NDUFS7, NDUFB5,
NDUFS3, NDUFB10, NDUFS1, NDUFA5,
NDUFB9, UFSP2, NDUFV2, NDUFS8, NDUFC2,
NDUFA7,NDUFS4,NDUFA8
NDUFS1, UFSP2, NDUFV2, NDUFS8, AS3MT,
NDUFS3
SDHA,SUCLA2,SDHB,SUCLG2,SUCLG1,DLD,
IDH2, MDH1, MDH2, CL YBL, IDH3B
SDHA, IDH2, MDH2, IDH3B
PSMA3, PSMA7, UBE2D2, USP48, TCEB2,
STUB1, USP47, USP16, UBE2E3, BRCA1,
PSMA2, ANAPC11, UCHL3, PSMB5, PSMD13,
UBE2R2 (includes EG:54926), PSME2, USP30,
USP1, PSMA1, UBE2L6, USP33, PSMD8, USP31,
PSMB7, PSMB2, PSMD12, PSMA4
USP31, PSMA6, PSMA3, PSMB5, PSMB10,
PSMA7, STUB1, UBE2R2 (includes EG:54926),
USP11, UBE2D2, UBR1, USP48
SDHA, ALDH4A1, SDHB, SUCLG2, MCS, DBT,
ALDH3B1, MY05B, DCXR, HMGCL, ALDH5A1,
ALDH9A1
SDHA, ALDH4A1, BDH1, MCS, ALDH3B1,
MY05B,PDHB,ALDH5A1,PRDX6,ACADS
ALDH4A1, HIBCH, SUCLA2, SUCLG2, SUCLG1,
ALDH3B1, MUT, ACAD10, UEVLD, ALDH5A1,
ALDH9A1
ALDH4A1, HIBCH, ACSM5, ACACB, DHCR24,
ALDH3B1, MUT, ACAD10, UEVLD, ALDH5A1,
ACADS
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Glycine, Serine and
Threonine Metabolism
Inositol Metabolism

GeneSpring
GeneSpring

Glutamate Metabolism

GeneSpring

Glutamate Metabolism

Partek

Valine, Leucine and
Isoleucine Degradation
Valine, Leucine and
Isoleucine Degradation
LPSIIL-1 Mediated
Inhibition of RXR Function

GeneSpring
Partek
GeneSpring

LPS/IL-1 Mediated
Inhibition of RXR Function

Partek

Pyruvate Metabolism

GeneSpring

Pyruvate Metabolism

Partek

GeneSpring
Glycolysis/Gluconeogenesi
s
Partek
Glycolysis/Gluconeogenesi
s

SARDH, GAMT, DLD, GARS, DBT, ALAS 1,
PDPR, SMOX, PISD, ABP1, PLCD4, ETNK2
COX6B1, AIFM3, OXNAD1, COX6C, BLVRB,
TPI1, TM7SF2, NDUFB10, CYB5RL, RP3402G11.5, IDH3B, NDUFA7, NDUFA8
ALDH4A1, SUCLG2, NADSYN1, GLUL, MY05B,
PPAT, ALDH5A1
ALDH4A1, NAGK, NADSYN1, GPT, MY05B,
GPT2, ALDH5A 1
ALDH4A1, HIBCH, DBT, ALDH3B1, AOX1, MUT,
HMGCL, ACAD10, ALDH5A1, ALDH9A1
ALDH4A1, HIBCH, MCCC1, ALDH3B1, MUT,
ACAD10, ALDH5A1, ACADS
ALDH4A1, GSTM3 (includes EG:2947), GSTA5,
ALDH9A1, IRAK1, SLC27A5, TRAF2, GSTA4,
GSTM4, ALAS1, ACSL4, SMOX, ALDH3B1, PLTP,
FABP3,SULT1C3,NDST1,SULT1B1,ALDH5A1
ALDH4A1, SUL T1C2, GSTM1, GSTM3 (includes
EG:2947), GSTA5, SLC01A2, GSTA4, CYP7A1,
GSTM4, ALDH3B 1, FABP7, PL TP, SULT1 C3,
LBP, ABCC3, NDST1, ABCC4, CYP2A6,
SULT1B1, ALDH5A1
ALDH4A1, LDHD, DLAT, DLD, ALDH3B1, ME1,
MDH1, MDH2, UEVLD, ALDH5A1, ALDH9A1
ALDH4A1, AKR1A1, ACSM5, ACACB, LDHD,
DLAT, ALDH3B1, ME1, MDH2, UEVLD, PDHB,
ALDH5A1
ALDH4A1, PGM1, GAPDH (includes EG:14433),
TPI1, ALDH9A1, ADH5 (includes EG:128), GPI,
EN01,DLAT,GALK1,DLD,ALDH3B1,UEVLD,
ALDH5A1
ADH5 (includes EG:128), ALDH4A1, AKR1A1,
ACSM5, DLAT, PGM1, ALDH3B1, TPI1, UEVLD,
PDHB, ALDH5A1

Table 2: Top IPA canonical pathways. Table shows Ingenuity Canonical
Pathways, the analysis that produced it, and the molecules that enrich the
pathway.
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A} GeneSpring

Functional
Cluster
1
2

Enrichment
Score
44.4
20.8

Category

Term

%

p-value

GOTERM CC FAT
KEGG_PATHWAY

GO:0005739~mitochondrion

21.8
4.2

2.39E-57
7.02E-21

2

20.8

GOTERM_BPJAT

3.0

1.16E-14

5.5
4.0
3.8

1.85E-16

mmuOO190:0xidative
phosphorylation
GO:0022900~electron

transport chain
3
3
4

9.9
9.9
9.0

GOTERM BP FAT
GOTERM CC FAT
GOTERM_BPJAT

GO:0006412~translation
GO:0005840~ribosome
GO:0051186~cofactor

1.66E-13
2.25E-14

metabolic process

B}Partek

Functional
Cluster
1
2
2
4

Enrichment
Score
13.6
11.1
11.1
2.3

Category

Term

%

p-value

GOTERM CC FAT
GOTERM BP FAT
GOTERM CC FAT
INTERPRO

GO:0005739~mitochondrion

15.0
5.2
4.0
1.7

1.42E-20
9.03E-14
2.81E-13
1.07E-04

GO:0006412~translation

GO :0005840~ri bosome
IPR012335:Thioredoxin fold

Table 3: DAVID analysis on gene expression. Tables show enriched terms
using lists from (A) GeneSpring and (8) Partek where pSO.01 with any

Fe

indicate similar terms are enriched using DAVID. Listed are one (or more)
representative terms for a functional cluster, along with the category that term
came from, the percent (%) enrichment that is the number of genes from the
input list vs. all the genes in the term, and p-value of enrichment.
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8.s3E-04

foldchange
1.403

ATPsA1

3.74E-03

1.214

ATPsA1

3.74E-03

1.214

ATPsC1

1.68E-04

1.349

Gene
Symbol
AIFM1

p-value

ATPsC1

1.68E-04

1.349

ATPsF1

1.97E-04

1.183

ATPsG1

1.8sE-03

1.138

ATPsG2

2.22E-03

1.175

ATPsH

2.33E-04

1.199

ATPsl

1.83E-03

1.152

ATPsJ

2.12E-03

1.103

ATPsJ

2.12E-03

1.103

ATPsJ2

6.82E-03

1.163

ATPsO

1.40E-04

1.222

ATP6V1A

s.31E-03

1.152

COX411

2.13E-03

1.23

COXsB

6.77E-04

1.225

COXsB

6.77E-04

1.225

COX6B1

1.47E-03

1.236

COX6B1

1.47E-03

1.236

COX6C

s.21E-03

1.162

COX6C

s.21E-03

1.162

COX7A2

7.7sE-03

1.192

COX7A2

7.7sE-03

1.192

COX7C

1.43E-03

1.238

COX7C

1.43E-03

1.238

GPX4

2.1sE-04

1.396

NDUFA4

8.20E-03

1.266

NDUFA4

8.20E-03

1.266

NDUFAs

3.32E-03

1.248

NDUFAs

3.32E-03

1.248

NDUFA7

7.16E-03

1.137

NDUFA7

7.16E-03

1.137

NDUFA8

s.52E-03

1.22

NDUFA8

s.52E-03

1.22

NDUFB10

1.09E-03

1.266

NDUFB10

1.09E-03

1.266

NDUFBs

1.92E-03

1.224

Description
apoptosis-inducing factor, mitochondrionassociated, 1
ATP synthase, H+ transporting, mitochondrial

cytochrome c oxidase subunit

glutathione peroxidase 4 (phospholipid
hydroperoxidase)
NADH dehydrogenase (ubiquinone)
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NDUFB5

1.92E-03

1.224

NDUFB9

3.22E-03

1.127

NDUFB9

3.22E-03

1.127

NDUFC1

3.08E-03

1.127

NDUFC2

2.48E-03

1.373

NDUFS1

7.45E-04

1.359

NDUFS1

7.45E-04

1.359

NDUFS3

6.59E-04

1.256

NDUFS3

6.59E-04

1.256

NDUFS4

6.04E-03

1.238

NDUFS4

6.04E-03

1.238

NDUFS7

4.55E-03

1.286

NDUFS7

4.55E-03

1.286

NDUFS8

2.76E-04

1.332

NDUFS8

2.76E-04

1.332

NDUFV1

2.13E-03

1.214

NDUFV1

2.13E-03

1.214

NDUFV2

9.24E-03

1.29

NDUFV2

9.24E-03

1.29

PPA2

8.23E-04

1.26

PRDX3

1.71E-03

1.381

peroxiredoxin 3

SDHA

1.16E-03

1.269

succinate dehydrogenase complex, subunit

SDHA

1. 16E-03

1.269

SDHB

2.43E-04

1.239

SDHB

2.43E-04

1.239

SOD2

1.75E-03

1.169

superoxide dismutase 2, mitochondrial

TCIRG1

9.47E-04

1.303

T-cell, immune regulator 1, ATPase, H+
transporting

TXN2

6.60E-03

1.247

thioredoxin 2

TXNRD2

2.51E-03

1.368

thioredoxin reductase 2
ubiquinol-cytochrome c reductase

UQCR10

1. 16E-03

1.185

UQCRll

4.17E-03

1.176

UQCRB

2.95E-03

1.175

UQCRB

2.95E-03

1.175

UQCRC2

1.76E-03

1.274

UQCRC2

1.76E-03

1.274

pyrophosphatase (inorganic) 2

Table 4: DAVID and IPA mitochondrion analysis. Table shows genes that
are common between DAVID GO term mitochondrion and IPA pathways
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mitochondrial dysfunction and oxidative phosphorylation with transcript p-value
and fold-change. Of the 78 genes between the 2 IPA pathways, 72 genes
appear in the DAVID GO term mitochondrion.
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No. Unique Genes
MicroRNA

TargetScan

Intersection

miRBase

Notes

mmu-miR-140

158

1000

43

140/876-3p

mmu-miR-18

125

2051

71

18ab

mmu-miR-206

478

861

61

1/206

mmu-miR-337
Totals

0

0

0

761

3912

175

Table 5: MicroRNA database comparison. Table shows number of predicted
microRNA gene targets found in TargetScan and miRBase. MicroRNA was input
into each database and predicted gene targets were collected. MiRBase
reported many more predicted gene targets than TargetScan. Notes indicate
TargetScan microRNA that have the same predicted targets; i.e. entering miR-1
or miR-206 in TargetScan will result in the same gene list.
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Figure 4: MicroRNA database comparison network. The top 2 networks from
the IPA analysis of the intersection of miRBase and TargetScan for micro RNA
predicted target genes indicate enrichment of different regulatory processes.
The top functions of network 1 (top) are tissue morphology, cellular growth and
proliferation, and gene expression and network 2 (bottom) are cancer, cell
morphology, and DNA replication, recombination, and repair. Gene symbols are
located in the center of each box. Colors represent those genes significantly
expressed and upregulated (red) in the GeneSpring dataset. A legend can be
found in Figure 3.
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Figure 5: MicroRNA and transcript intersection comparison network. The
top 2 networks from the IPA analysis of the intersection of miRBase predicted
gene targets and transcript genes where p:50.01 with any fold-change indicates
networks similar in function to the transcript gene set. The top functions
associated with each of the networks follows: cell death, hematological system
development and function, and inflammatory disease (top) and cellular
development, cell death, and cell signaling (bottom). A legend can be found in
Figure 3.
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Functional
Cluster
1

Category

Term

% Enrichment

p-value

GOTERM_BP_ALL

GO:0065007~

44.3

1.60E-08

18.2

6.39E-07

23.9

8.09E-07

10.8

4.42E-07

9.0

4.41E-05

5.7

1. 14E-04

4.6

6.94E-04

15.3
29.6

9.19E-05
2.28E-03

biological
regulation
1

GOTERM_MF_ALL

GO:0030528~

transcription
regulator
activity
1

GOTERM_MF _ALL

GO:0003677~

2

GOTERM_BP_ALL

GO:0009790~

DNA binding
embryonic
development
3

GOTERM_BP _ALL

GO:0006366~

transcription
from RNA
polymerase II
promoter
4

GOTERM_BP _ALL

GO:0048514~

blood vessel
morphogenesi
s
4
5
5

GOTERM_BP_ALL
SP PIR KEYWORDS
GOTERM_MF_ALL

GO:0001525~

angiogenesis
zinc-finger
GO:0046872~

metal ion
binding

Table 6: MicroRNA and transcript intersection DAVID analysis. Listed in
this table are enriched terms for the micro RNA predicted gene targets,
implicating many transcriptional regulatory networks. Listed are one (or more)
representative terms for a functional cluster, along with the category that term
came from, the percent (%) enrichment that is the number of genes from the
input list vs. all the genes in the term, and p-value of enrichment.
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Enriched with

FoldChang
e*
NC

TF name

No.
genes

Enrichment
factor

M00292[Freac-4]

23

1.779

Foxd1 forkhead box D1

M00997[DEC]

19

1.974

M01066[BLlMP1]

23

1.453

M00134[HNF-4]

18

1.347

MOO026[RSRFC4]

21

1.338

Bhlhe40 basic helix-loop-helix family,
member e40
Prdm1 PR domain containing 1, with
ZNF domain
Pparg peroxisome proliferator activated
receptor gamma
Same as Mef2a ??

M00146[HSF1]

12

1.527

Heat shock factor protein 1

NC

M00626[RFX1_(EF
-C)]
MOO055[N-Myc]

23

1.797

NC

20

1.262

M00403[aMEF-2]

17

1.348

Rfx1 regulatory factor X, 1 (influences
HLA class II expression)
Mycn v-myc myelocytomatosis viral
related oncogene, neuroblastoma
derived (avian)
Mef2a myocyte enhancer factor 2A

8

1.391

Srf serum response factor

NC

M00191[ER]

17

1.441

Esr1 estrogen receptor 1 (alpha)

M01004[Helios_A]

20

1.741

Ikzf2 IKAROS family zinc finger 2

M00279[MIF-1]

21

1.502

Gm4924 predicted gene 4924

M00114[TaxlCREB]

21

1.673

M00196[Sp1]

51

1.236

tax p40 [ Human T -Iymphotropic virus 1 ]
and Creb1 cAMP responsive element
binding protein 1
Sp1 trans-acting transcription factor 1

NC

M00447[AR]

17

1.642

Ar androgen receptor

NC
NC

M00186[SRF]

1.5 fc
(1.2)-fc
1.6 fc
NC

NC

NC
1.3 fc
NC
NC

M00963[T3R]

20

1.636

Rxra retinoid X receptor alpha

MOOO05[AP-4]

18

1.381

Tcfap4 transcription factor AP4

NC

M00322[cMyc:Max]

25

1.343

Myc myelocytomatosis oncogene

1.6 fc
myc

*Fold-change In arsenic exposed vs. not exposed If FC

~

11.11. otherwise no

change (NC). Parentheses represents negative value.
Table 7: TFBS analysis on gene expression. Listing of significantly enriched
Transcription Factor Binding Sites (TFBS), from significantly differentially
expressed genes in GeneSpring dataset where

p~O.05

and

FC~11.51.

All TFBS

where p::;;O.05 are presented along with the transcription factor that binds the site,
number of genes involved in our list (out of 94 genes), and enrichment factor, the
fold-change (FC) of the TF was provided if it was available in our original gene
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data if the Fe was more than 1.1 fold. TFs were resolved from the TFBS 10
using MAPPER (http://snpper.chip.org/mapper/mapper-main).
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Figure 6: TFBS on gene list clustering. Transcription factor binding sites and
genes used to find enriched TFBS (filtered where

p~O.05

and FC>I±1.51). A

yellow box indicates the gene (on the rows) was found to contain a TFBS (on the
columns). Clusters are formed on columns and rows using McQuitty's Criteria in
PermutMatrix (http://www.lirmm.fr/-carauxlPermutMatrixl).
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